Analyst Trims Vivus Target and 4 Stock Analyses Making Rounds
Vivius Inc. (NASDAQ:VVUS): After the company disclosed shipped prescriptions of Qsymia on their third quarter earnings call, which indicated actual demand is tracking 30% below IMS data, Jefferies lowered their price target for Vivius Inc. The firm keeps an Underperform rating on their stock.
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL): After Pfizer (NYSE:PFE) priced their competitor’s Jak Inhibitor Xeljanz higher than expected, Jefferies said they have increased their confidence in Rigel Pharmaceuticals’s Fostamatinib opportunity. The firm keeps a Buy rating on shares of Rigel with an increased price target or $21.
Catalysts are critical to discovering winning stocks. Check out our newest CHEAT SHEET stock picks now.
Activision Blizzard, Inc. (NASDAQ:ATVI): Piper Jaffray is more confident that estimates for Activision Blizzard, Inc. will increase as they believe that new data indicates that the company’s Skylanders Giants game is outperforming expectations. The firm finds the stock’s valuation compelling and reiterates a $14 target and Overweight rating.
Cogent Communications Group Inc. (NASDAQ:CCOI): Following good third quarter results, Cowen said that Cogent Communications Group Inc. remains well positioned for 2013. The firm noted improved traffic growth, expectations for meaningful dividend growth, and the possibility for double digit revenue growth. Shares are Outperform rated.
Amgen Inc. (NASDAQ:AMGN): RBC Capital predicted that investors’ interest in Amgen Inc.’s late stage cardiovascular drug AMG-145 will increase over the next year. The firm anticipates that the drug could represent a $10 billion+ market opportunity for Amgen and they recommend buying their stock.